Company intelligence / Profile preview
Poxel SA
Lyon, Rhône-Alpes, Francepoxelpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TWYMEEG (Imeglimin) is approved and marketed in Japan for Type 2 diabetes. PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a Phase 2 trial for NASH. PXL770 is in mid-stage development as a first-in-class AMPK activator for rare diseases.
- Therapeutic areas
- GastroenterologyEndocrinologyNeurologyMetabolic Disorders
- Modalities
- Small moleculesdeuterium-modified thiazolidinedione (dTZD)AMPK activators
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sumitomo Pharma (marketing TWYMEEG in Japan)
Beyond the preview
Go deeper on Poxel SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poxel SA.